Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes - PubMed (original) (raw)
Comparative Study
. 2006 Aug 1;108(3):836-46.
doi: 10.1182/blood-2005-11-4503. Epub 2006 Apr 4.
Simona Iacobelli, Ronald Brand, Thekla Jansen, Anja van Biezen, Jürgen Finke, Andrea Bacigalupo, Dietrich Beelen, Jossy Reiffers, Agnes Devergie, Emilie Alessandrino, Ghulam J Mufti, Renée Barge, Jorge Sierra, Tapani Ruutu, Marc Boogaerts, Michele Falda, Jean-Pierre Jouet, Dieter Niederwieser, Theo de Witte; Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group
Affiliations
- PMID: 16597592
- DOI: 10.1182/blood-2005-11-4503
Free article
Comparative Study
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
Rodrigo Martino et al. Blood. 2006.
Free article
Abstract
In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with a human leukocyte antigen (HLA)-identical sibling donor were analyzed according to 2 types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high-dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (hazard ratio [HR], 1.64; 95% confidence interval [95% CI], 1.2-2.2; P = .001), but the 3-year nonrelapse mortality (NRM) rate was decreased in the RIC group (HR, 0.61; 95% CI, 0.41-0.91; P = .015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SMC vs 33% in RIC; multivariate P = .9; and 45% vs 41%, respectively; P = .8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age > 50 years in 73% RIC vs 28% in SMC, P < .001) and had more adverse pretransplantation variables. However, based on the higher risk of relapse, patients with no contraindications for SMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS.
Similar articles
- The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A. Solh MM, et al. Biol Blood Marrow Transplant. 2019 Mar;25(3):606-612. doi: 10.1016/j.bbmt.2018.09.012. Epub 2018 Sep 19. Biol Blood Marrow Transplant. 2019. PMID: 30244109 - Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT. Chen YB, et al. Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2. Biol Blood Marrow Transplant. 2013. PMID: 23562738 - Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.
Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N. Martino R, et al. Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20. Bone Marrow Transplant. 2017. PMID: 28319072 - Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
Zhang ZH, Lian XY, Yao DM, He PF, Ma JC, Xu ZJ, Guo H, Zhang W, Lin J, Qian J. Zhang ZH, et al. J Cancer Res Clin Oncol. 2017 Sep;143(9):1853-1864. doi: 10.1007/s00432-017-2429-z. Epub 2017 May 3. J Cancer Res Clin Oncol. 2017. PMID: 28470473 Review.
Cited by
- Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
Orchard K, Langford J, Guy M, Lewis G, Michopoulou S, Cooper M, Zvavamwe C, Richardson D, Lewington V. Orchard K, et al. Bone Marrow Transplant. 2024 Sep;59(9):1247-1257. doi: 10.1038/s41409-024-02317-z. Epub 2024 Jun 12. Bone Marrow Transplant. 2024. PMID: 38867006 Free PMC article. Clinical Trial. - Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients.
Pan M, Wu Y, Yang L, Zhu P, Shi J, Lai X, Liu L, Zhao Y, Yu J, Huang H, Luo Y. Pan M, et al. Ann Hematol. 2024 Aug;103(8):3105-3119. doi: 10.1007/s00277-024-05819-4. Epub 2024 Jun 3. Ann Hematol. 2024. PMID: 38829409 - Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy.
Itonaga H, Miyazaki Y, Fujioka M, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, Katayama Y, Ota S, Kawakita T, Kato J, Matsuoka KI, Eto T, Onizuka M, Ichinohe T, Atsuta Y, Ishiyama K. Itonaga H, et al. Bone Marrow Transplant. 2024 Aug;59(8):1107-1117. doi: 10.1038/s41409-024-02297-0. Epub 2024 May 7. Bone Marrow Transplant. 2024. PMID: 38714756 - Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.
Antier C, Jullien M, Tessoulin B, Loirat M, Peterlin P, Garnier A, Le Bourgeois A, Chevallier P, Guillaume T. Antier C, et al. Cancers (Basel). 2024 Apr 5;16(7):1419. doi: 10.3390/cancers16071419. Cancers (Basel). 2024. PMID: 38611097 Free PMC article. - Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.
Popat UR, Pasvolsky O, Bassett R Jr, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Popat UR, et al. Blood Adv. 2023 Oct 24;7(20):6196-6205. doi: 10.1182/bloodadvances.2023010850. Blood Adv. 2023. PMID: 37611156 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous